

PERSONAL INFORMATION

Hugues Malonne

WORK EXPERIENCE

April 2022- Present

Director General Pre authorisation

Federal Agency for Medicines and Health Products (Belgium)

The FAMHP is the Belgian competent authority for the quality, safety and efficacy of medicines and health products. The DG Pre Authorization is in charge of all the activities taking place before the first marketing authorisation for a medicine or a healthcare product. The DG regroups 4 divisions and 2 units: the R&D Division, the Marketing Authorization Division, the Veterinary Medicine Division, the Evaluator Division, the National Innovation Office and the Pharmacopeia/API unit. The FAMHP is the Belgian competent authority for the quality, safety and efficacy of medicines and health products. The DG Pre Authorization is in charge of all the activities taking place before the first marketing authorisation for a medicine or a healthcare product. The DG regroups 4 divisions and 2 units: the R&D Division, the Marketing Authorization Division, the Veterinary Medicine Division, the Evaluator Division, the National Innovation Office and the Pharmacopeia/API unit.

February 2017-March 2022

Director General Post authorisation

Federal Agency for Medicines and Health Products (Belgium)

The FAMHP is the Belgian competent authority for the quality, safety and efficacy of medicines and health products. The DG Post Authorization is in charge of all the activities taking place after the first marketing authorisation for a medicine or a healthcare product. The DG regroups 4 divisions: the Post Authorization Division, the Vigilance Division, the Healthcare Products Division and the Proper Use Division.

September 2018- Present

Invited Professor

University of Namur (Belgium)

Part-time activity in the fields of pharmacology, healthcare innovation and financing.

June 2013- Present

Professor

Université libre de Bruxelles (Belgium)

Part-time activity in the fields of pharmacology, healthcare innovation and financing.

June 2013-December 2019

Independent Director, Board of Directors

Luxembourg Institute of Health/Integrated Biobank of Luxembourg (Luxembourg)

The Luxembourg Institute of Health is the result of the merger of former Centre de Recherche Public- Santé and the Integrated Biobank of Luxembourg. The Luxembourg Institute of Health is a public biomedical research organization. Striving for excellence, its researchers, by their creativity, enthusiasm and commitment, generate knowledge on disease mechanisms and contribute to the development of new diagnostics, innovative therapies and clinical applications that impact the healthcare of Luxembourgish and European citizens. The activities of the Luxembourg Institute of Health are developed within the following research topics: Oncology, Infection and Immunity, Population Health.

The IBBL (Integrated BioBank of Luxembourg) Institute is a biobank dedicated to supporting biomedical research for the benefit of patients. The mission of IBBL is to provide high quality biospecimens and associated data, foster scientific excellence, catalyse partnerships and support research that translates scientific discoveries into new healthcare solutions. IBBL is an integrated research infrastructure, compliant with international quality standards, offering biobanking services, including the collection, processing, analysis and storage of biological samples and associated data. In addition, IBBL carries out research to optimise biospecimen processing and certify biospecimen quality.

The Board of Directors oversees all the above mentioned activities.

June 2013-January 2017

Managing Partner

Alpine Partners AG (Switzerland)

Based in Lucerne, Alpine Partners is a boutique consulting firm specializing in healthcare innovation. We provide a large set of services and expertise in the fields of Market Access (pricing and reimbursement), Public-Private Partnerships, Medical/Scientific Affairs, Training/coaching and Marketing Strategy.

Our clients are global healthcare companies (pharmaceuticals, medical devices, diagnostics and consumer goods), mid-sized biotech firms, governmental bodies and NGOs.

December 2011-December 2012 **Divisional Director, Global Value Proposition, EPD HQ**

Abbott Laboratories (Switzerland)

Market Access Leadership Team member, reporting to the Global Head of Market Access

Member of the EMEA West Leadership Team, dotted-line reporting to the Area Vice-President EMEA-W*

Core job responsibilities:

- Define EPD Global Value Proposition versus pure generics, analyze potential value dimensions and hypothesis
 - Collaborate with external opinion leaders and research groups to generate public health evidences to sustain value claims
 - Design and execute Outcomes Research projects and initiatives to support the Value Proposition
 - Provide guidance on related health policy platform engagement in close collaboration with government affairs colleagues, country GMs and Area VPs
 - Monitor health policy environment, anticipate trend and changes, proactively adjust and adapt EPD Value Proposition and related activities
 - Provide strategic input into portfolio optimization to support/enhance EPD Value Proposition
- * Support the country separation process for EMEA-W providing guidance for the newly created country and area level Market Access & Policy structure

January 2009-December 2011 **Head, Public Policy & HEOR (later Public Policy & Market Access) MSD (Merck & Co) (China)**

Country Management Team member, reporting to the Chairman and President MSD China

Health Outcomes:

Managed and coached a team of 7 people who develop and implement outcomes research studies and initiatives supporting key therapeutic areas (ID, Diabetes, Ophthalmology, CV, Respiratory, Vaccines, Oncology)

Major achievements:

- Developed and implemented one of the largest real world outcomes study for patients with type 2 diabetes (acronym: 3B, 25000 patients) and its extension

Public Policy:

Led a team of 3 people to develop, launch and implement innovative multi-year Public-Private Partnerships in ID and CV-metabolism

Major achievements:

- Partnership with the Sichuan Health Bureau on integrated and standardized management of hypertension, dyslipidemia, and type 2 diabetes (target population for pilot phase: 2 million inhabitants)
- Partnership with China Center for Disease Control and Prevention on viral hepatitis (includes health outcomes research, medical and public education, health policy advocacy)
- Several partnerships with City Governments on chronic disease management

2005- 2009 **External Affairs Director, MSD Belgium-Luxembourg**

MSD (Merck & Co) (Belgium)

In charge of Market Access, Governmental Affairs and Public Relations (Spokesperson)

Country Management Team member, reporting to the General Manager MSD Belgium

Head of a team of 12 people

1999- 2005 **Senior Lecturer-Associate Professor-Professor**

Université libre de Bruxelles (Belgium)

Extensive teaching and research experience in:
Pharmacology (pharmacokinetics and pharmacodynamics)
Pharmaceutics and Biopharmaceutics
Ethics and Regulations (including Market Access)

EDUCATION AND TRAINING

- October 2015-October 2016 **Executive Master in Healthcare Management (MMISS)**
Solvay Brussels School (Université libre de Bruxelles) (Belgium)
Hospital and Health Care Facilities Administration/Management
- March 2011-March 2011 **Certificate in Critical Issues in Tumor Microcirculation, Angiogenesis and Metastasis**
Harvard Medical School (United States)
Oncology continuing education program
- 1993- 1999 **PhD, Pharmaceutical Sciences (Pharmacology)**
Université libre de Bruxelles (Belgium)
Pre-clinical pharmacology
Oncology
Biopharmaceutics and pharmaceutics
- 1988- 1993 **Pharmacist (PharmD)**
Université libre de Bruxelles (Belgium)

ADDITIONAL INFORMATION

- Expertise** Oncology, Pain, Diabetes, Anti-infective drugs, Biological products and Biosimilars, Pharmacokinetics, Modified-release formulations
- Publications**
1. Study of potential depot systems composed of polar lipids and water including various hydrophilic and hydrophobic drugs
H. MALONNE, A.J. MOES, J. FONTAINE.
Acta Technologiae et Legis Medicamenti, 1996, 1(3), 165-170.
 2. Le traitement de la douleur dans le cadre de l'officine
H. MALONNE, L. LEEMANS, J. FONTAINE.
J. Pharm. Belg., 1996, 2.1(6), 305-315.
 3. Pijn in de officina: farmacologische beschouwingen deel I
L. LEEMANS, H. MALONNE, G. LAEKEMAN.
Farm. Tijdschr., 1996, 2(12), 3-12.
 4. Pijn in de officina: communicatie als hoofdoel van het baliegebeuren deel II
L. LEEMANS, H. MALONNE, G. LAEKEMAN.
Farm. Tijdschr., 1996, 2(12), 13-17.
 5. DNA topoisomerases targeting drugs: mechanisms of action and perspectives
H. MALONNE, G. ATASSI.
Anticancer Drugs, 1997, 11(9), 811-822.
 6. Les interactions médicamenteuses: I Principes généraux
H. MALONNE, J. FONTAINE.
J. Pharm. Belg., 1997, 52(1), 41-48.
 7. Les interactions médicamenteuses: II Exemples rencontrés dans le traitement des pathologies digestives
H. MALONNE, J. FONTAINE.
J. Pharm. Belg., 1997, 52(2), 65-68.
 8. Topical anti-inflammatory activity of new 2-(1-indoliziny)propionic acid derivatives in mice
H. MALONNE, J. HANUISE, J. FONTAINE.
Pharm. Pharmacol. Commun., 1998, 1(3), 241-244.

9. Interactions entre médicaments et aliments modifiant l'absorption du principe actif
H.MALONNE.
Dieta, 1998, 11, 14-18.
10. Characterization of biological features and chemosensitivity of a new experimental lung metastasis model originating from the MXT mouse mammary adenocarcinoma
S. FARINELLE, R. DEDECKER, H. MALONNE, J. WERRY, F. DARRO, R. KISS.
Anticancer Res., 1999, 19(2A), 1171-1180.
11. Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors
H. MALONNE, I. LANGER, R. KISS, G. ATASSI.
Clin. Exp. Metastasis, 1999, 11(1), 1-18.
12. Les Céphalées chroniques journalières
H. MALONNE.
Neurone, 1999, 4(5), 150-3.
13. Homocamptothecin, an E-ring modified camptothecin exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under organotypical cultures conditions
P. PHILLIPART, L. HARPER, C. CHABOTEAUX, C. DECAESTECKER, Y. BRONCKART, L. GORDOVER, L. LESUEUR-GINOT, H. MALONNE, O. LAVERGNE, D.C.H. BIGG, P. MENDES DA COSTA, R. KJSS.
Clin. Cancer Res., 2000, 6(4), 1557-62.
14. In vitro/in vivo characterisation of a tramadol HCl depot system composed of monoolein and water
H. MALONNE, J. FONTAINE, A.J. MOES.
Biol. Pharm. Bull., 2000, 23(5), 627-31.
15. Characterization of TNP-470-induced modifications on cell proliferation and apoptosis in HUVEC and cancer cells
S. FARINELLE, H. MALONNE, C. CHABOTEAUX, R. DEDECKER, T.GRAS, D. ZUNE, F. DARRO, J. FONTAINE, G. ATASSI, R. KISS., J.FONTAINE
Pharmacol. Toxicol. Methods, 2000, 43(1), 15-24.
16. In vitro and in vivo pharmacological characterizations of the anti-tumor properties of two new olivacine derivatives, SI6020-2 and S30972-I
H. MALONNE, S. FARINELLE, C. DECAESTECKER, L. GORDOWER, J. FONTAINE, F.CHAMINADE, J.M. SAUCIER, G. ATASSI, R. KISS.
Clin. Cancer Res., 2000, 6(9), 3774-82.
17. Développement préclinique de nouvelles molécules à visée antitumorale: études pharmacologiques et toxicologiques
H. MALONNE, J. GUSMAN, G. ATASSI.
J. Pharm. Belg., 2000, 55(5), 122-30.
18. A reappraisal of potential chemopreventive and chemotherapeutic properties of resveratrol
J. GUSMAN, H. MALONNE, G. ATASSI.
Carcinogenesis, 2001, 22(8), 1111-7.
19. Le traitement de la diarrhée aiguë, évaluation critique par un groupe interuniversitaire et recommandations. Partie I : Importance du problème
D. URBAIN, J. BELAICHE, M. DE VOS, R. FIASSE, M. HIELE, S. HUIJGHEBAERT, F. JACOBS, H. MALONNE, P. SPEELMAN, J. STERNON, A. VAN GOSSUM, E. VAN WIJNGAERDEN
Louvain Med., 2001, 120(10), 354-61.
20. Le traitement de la diarrhée aiguë, évaluation critique par un groupe interuniversitaire et recommandations. Partie II : Revues des options thérapeutiques
D. URBAIN, J. BELAICHE, M. DE VOS, R. FIASSE, M. HIELE, S. HUIJGHEBAERT, F. JACOBS, H. MALONNE, P. SPEELMAN, J. STERNON, A. VAN GOSSUM, E. VAN WIJNGAERDEN
Louvain Med., 2001, 120(10), 362-72.
21. Le traitement de la diarrhée aiguë, évaluation critique par un groupe interuniversitaire et recommandations. Partie III Revues des options thérapeutiques
D. URBAIN, J. BELAICHE, M. DE VOS, R. FIASSE, M. HIELE, S. HUIJGHEBAERT, F. JACOBS, H. MALONNE, P. SPEELMAN, J. STERNON, A. VAN GOSSUM, E. VAN WIJNGAERDEN

- Louvain Med., 2002, 121(1), 18-25.
22. Cardiotoxicite du 5-fluorouracil: A propos de 6 nouveaux cas
Q. TIMOUR, C. LOMBARD-BOHAS, R. SLIM, C. BAREL, B. BUI-XUAN, A.TAHIB, G. BRICCA, H. MALONNE, T. VIAL, D. IORDESCU, J. DESCOTES.
Therapie, 2002, 57(3), 302-6.
23. Differences in efficacy found in animal between recombinant forms of erythropoietin will not necessarily translate into differences in humans
H. MALONNE.
Br. J. Cancer, 2002, 87(4), 475-7.
24. Conseils en pharmacie pour l'automedication de la diarrhee aigue
L. LEEMANS, J. BURTON, C. ELSSEN, S. HUIJGHEBAERT, T. LESCRINIER, H. MALONNE, F. NAGELS, F. NIESTEN
Ann. Pharm. Belg., 2002, 52(6), 26-42.
25. Impact of montelukast on symptoms in mild- to moderate persistent asthma and exercise-induced asthma: Results of the ASTHMA Survey
H. MALONNE, A. LACHMAN, P. VAN DEN BRANDE
Curr. Med. Res. Opin. 2002, 18(8), 512-9.
26. Treatment of acute diarrhea: update of guidelines based on a critical interuniversity assessment of medications and current practices
D. URBAIN, J. BELAICHE, M. DE VOS, R. FIASSE, M. HIELE, S. HUIJGHEBAERT, F. JACOBS, H. MALONNE, P. SPEELMAN, A. VAN GOMPEL, A. VAN GOSSUM, E. VAN WIJNGAERDEN
Acta Gastroenterol. Belg., 2003, 66(3), 218-26.
27. The experience of menstrual pain in Belgian women
H. MALONNE, J. VAN HOEK.
In: Proceedings of the 10th World Congress on Pain, Progress in Pain Research and Management, Vol. 24, Edited by J.O. Dostrovsky, D.B. Carr and M. Koltzenburg, IASP Press, Seattle, 2003, 571-6.
28. Accidents cardio-vasculaires et coxibs; mythe ou realite?
H. MALONNE, D. FONTAINE
Science et Officine, 2003,2, 7-11.
29. Assessment of the pharmacokinetic profile of a new once daily oral formulation of tramadol hydrochloride after single and multiple dose administration in healthy volunteers
H.MALONNE, B. SONET, B. STREEL, S. LEBRUN, S. DE NIET, A. SERENO, F. VANDERBIST
Br. J. Clin. Pharmacol. 2004, 57(3), 270-8.
30. Phenolic compounds from *Plumbago zeylanica* and their cytotoxicity
A.T. NGUYEN, H. MALONNE, P. DUEZ, R. VANHAELEN-FASTRE, M. VANHAELEN, J. FONTAINE
Fitoterapia, 2004, 75(5), 500-4.
31. Aspects physiologiques et pharmacologiques des erythropoietines
H. MALONNE
J. Pharm. Belg., 2004, 59(2), 41-8.
32. Efficacy of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the knee and of the hip: A randomised, multicentre, placebo controlled, double-blind study
H. MALONNE, M. COFFINER, B. SONET, A. SERENO, F. VANDERBIST
Clin. Ther., 2004, 26(11),1774-82.
33. Long term tolerability of a new once-daily tramadol formulation in patients with osteoarthritis or low back pain
H. MALONNE, M. COFFINER, D. FONTAINE, B. SONET, A. SERENO, A. PERETZ, F. VANDERBIST
J. Clin. Pharm. Ther., 2005, 30(2), 113-20.
34. A sugar ester and an iridoid glycoside from *Scrophularia ningpoensis*.
A.T. NGUYEN, J. FONTAINE, H. MALONNE, M. CLAEYS, M. LUHMER, P. DUEZ
Phytochemistry, 2005 May, 66(10), 1186-91.

35. Preliminary assessment of the acute and subacute toxicity of poly(N-isopropylacrylamide) and copolymers in mice
H. MALONNE, F. EECKMAN, D. FONTAINE, A. OTTO, L. DE VOS, A. MOES, J. FONTAINE, K. AMIGHI
Eur. J. Pharm. Biopharm., 2005 Oct, 61(3),188-94.
36. Cytotoxicity of five plants used as anticancer remedies in Vietnamese traditional medicine
A.T. NGUYEN, J. FONTAINE, H. MALONNE, M. VANHAELEN, J. DUBOIS, T.K. PHAM, P. DUEZ
In: Recent Progress in Medicinal Plants, Edited by V.K. SINGH, ARUNACHALAM V.K. SINGH, J.N. GOVIL, Studium Press LLC, New Delhi, 2006, 145-155.
37. Homoisoflavanones from *Disporopsis aspera*.
A.T. NGUYEN, J. FONTAINE, H. MALONNE, P. DUEZ
Phytochemistry. 2006 Oct, 67(19), 2159-63.
38. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium.
L. ANNEMANS, D. STRENS, E. LOX, C. PETIT, H. MALONNE
Support Care Cancer, 2008 Aug, 16(8), 905-15.
39. The role of serology for COVID-19 control: Population, kinetics and test performance do matter.
M. TRE-HARDY, L. BLAIRON L, A. WILMET, I. BEUKINGA, H MALONNE, JM DOGNE, J. DOUXFILS
J Infect. 2020 Aug;81(2):e91-e92.
40. Evaluating Diagnostic Accuracy of Saliva Sampling Methods for Severe Acute Respiratory Syndrome Coronavirus 2 Reveals Differential Sensitivity and Association with Viral Load.
P. MESTDAGH, M. GILLARD, SK DHILLON, JP PIRNAY, J. POELS, J. HELLEMANS, V. HUTSE, C. VERMEIREN, M. BOUTIER, V. DE WEVER, P. SOENTJENS, S. DJEBARA, H. MALONNE, E. ANDRE, M. ARBYN, J. SMERAGLIA, J. VANDESOMPELE.
J Mol Diagn. 2021 Oct;23(10):1249-1258.

Projects

Memberships

Presentations at congresses

- Potential depot systems composed of polar lipids and water
H. MALONNE, A.J. MOES, J. FONTAINE.
Proceedings of the 2nd European Intensive Course on New Forms and New Routes of Administration for Drugs, Parme, Italie, 1996.
- Antitumour activity of S 16020-2 (NSC-659687) in the MXT mouse mammary carcinoma model
H. MALONNE, S. FARINELLE, J. FONTAINE, R. KISS, G. ATASSI. Proceedings of the 6th International Conference of Anticancer Research, Halkidiki, Grece, 1998 (publie dans Anticancer Res., 1998, 18, 4910).
- In vitro characterization of S 16020-2 induced effects on Human Umbilical Vein Endothelial Cells lines
H. MALONNE, S. FARINELLE, J. FONTAINE, G. ATASSI, R. KISS. Proceedings of the 6th International Conference of Anticancer Research, Halkidiki, Grece, 1998 (publie dans Anticancer Res., 1998, 18, 4910).
- Histological characterisation of a highly invasive and metastatic model originating from the P388 leukemia cell line
H.MALONNE, S. FARINELLE, D. FONTAINE, J. FONTAINE, R. KISS, G. ATASSI.
Reunion de la Societe Belge de Physiologie et de Pharmacologie Fondamentales et Cliniques, RUG, Gand, Belgique, 1999 (publie dans Pflugers Arch., 1999,437, R30).
- Pharmacological characterization of two new olivacine derivatives as potential anticancer drugs
H. MALONNE, S. FARINELLE, C. DECAESTECKER, J. FONTAINE, R. KISS, G. ATASSI.
Reunion de la Societe Belge de Physiologie et de Pharmacologie Fondamentales et Cliniques, Campus Erasme, ULB, Bruxelles, Belgique, 2000 (publie dans Pflugers Arch., 2000, 440, R7).

6. Characterisation of a tramadol HCl depot system composed of monoolein and water
H. MALONNE, J. FONTAINE, A.J. MOES. (Presentation orale)
9eme Forum de la Societe Belge des Sciences Pharmaceutiques, Blankenberge, Belgique, 2000
(publie dans J. Phann. Belg., 2000).
7. Quantitative assessment of angiogenesis in the chick embryo chorioallantoic membrane assay
and the effect of chitosan.
M.MALEKI, L.DEWACHTER, K.AMIGHI, H.MALONNE, J.FONTAINE
68eme Congres de la Societe de Physiologie, Liege, Belgique, 2000 (publie dans Pflugers Arch.,
2000, 440, R233-4).
8. Characterization of the effect of chitosan on angiogenesis in the chick embryochorioallantoic
membrane assay.
H.MALONNE, M.MALEKI, L..DEWACHTER, K.AMIGHI, J.FONTAINE
VIIIth International Metastasis Research Society Congress, Londres, Royaume-Uni, 2000 (publie
dans Clin. Exp. Metastasis, 1999, 11, 777).
9. Evaluation of different formulations of Paclitaxel nanoparticles
K. AMIGHI, I. GIL-DELGADO, H.MALONNE, J. GUSMAN, J.FONTAINE
10eme Forum de la Societe Belge des Sciences Pharmaceutiques, Montreal Canada, 2001.
10. Evaluation of the pharmacokinetic profile of a new once daily oral formulation of tramadol
hydrochloride in healthy volunteers
F.VANDERBIST, B. SONET, S. LEBRUN, S. DENIET, A. SERENO, H.
MALONNE.
3eme Reunion de la Federation des 25 Societes Europeennes de Pharmacologie (EPHAR), Lyon,
France, 2001 (publie dans Fund. Clin. Pharmacol., 2001.15.Sup 1, 30).
11. Preparation and characterization of paclitaxelloaded nanoparticles
I. GIL-DELGADO, H. MALONNE, J. GUSMAN, J.FONTAINE, K. AMIGHI. International Symposium
on Materials Characterisation and Technology Bruxelles, Belgique 2001.
12. Comparative pharmacodynamics and pharmacokinetics of triptans
H. MALONNE. (Oral presentation)
Neurogenetics and acute treatment of migraine. Autumn meeting of the BNS (Belgian Neurological
Society). Spa, Belgique. 2001.
13. Mechanism of 5-fluorouracil cardiotoxicity: spasm, apoptosis or necrosis?
Q. TIMOUR, C. LOMBARD-BOHAS, D. IORDACHESCU, B. BUI-XUAN, H.
MALONNE, T. VIAL, J. DESCOTES, L. CHALABREYSSE, A. TABIB. IUPHAR, San Francisco (Ca),
Etats-Unis, 2002.
14. Belgian women and menstrual pain
H. MALONNE, O. BAYARD, M. FOULON, M. VANSCHOOR, A. VIOLON, J.
WIELANDT, L. GOUBERT, J. VAN HOEK.
10th World Congress on Pain, International Association for the Study of Pain, San Diego (Ca),
Etats-Unis, 2002.
15. Les Cercles de Qualite; Interactions Pharmaciens-Medecins, le meilleur des deux mondes?
H.MALONNE.
Colloque <> Ecole de Pharmacie, Universite catholique de Louvain, Bruxelles, 2002.
16. Evaluation of the antiangiogenic potential of ACE inhibitors on the chick
chorioallantoic membrane model
C. CZERWONOGORA, D. FONTAINE, H. MALONNE, J. FONTAINE
Reunion de la Societe Belge de Physiologie et de Pharmacologie Fondamentales et Cliniques,
RUG, Gand, Belgique, 2002 (publie dans Fund. Clin. Pharmacol., 2003, 11(3), 272).
17. Isolation and structure determination of potential cytotoxic constituents from *Plumbago
zeylanica*
A.T. NGUYEN, H. MALONNE, P. DUEZ, R. VANHAELEN-FASTRE, J.
FONTAINE, M. VANHAELEN
27th Landelijk Overleg Farmacognosie Symposium (LOF), Anvers, Belgique, 2003.

18. The ASTHMA Survey: impact of montelukast on symptoms in mild- to moderate persistent asthma and exercise-induced asthma
H. MALONNE, A. LACHMAN, P. VAN DEN BRANDE
60th Anniversary Meeting of the American Academy of Allergy Asthma and Immunology (AAAAI), Denver (Co), Etats-Unis, 2003 (publie dans J. Allergy Clin. Immunol., 2003, 111(2), S144).
19. A phytochemical analysis and cytotoxic study of 2 Vietnamese medicinal plants *Scrophularia ningpoensis* Hemsl. and *Disporopsis aspera* Engl.
A.T. NGUYEN, H. MALONNE, J. FONTAINE, M. VANHAELEN, P. DUEZ.
51st Annual Congress of the Society for Medicinal Plant Research, Kiel, Allemagne, 2003.
20. Open, international, multicentre, PHASE III trial on the safety of a long-term treatment with a new sustained-release formulation of tramadol in patients suffering from osteoarthritis or from refractory chronic low back pain
H. MALONNE, M. COFFINER, B. SONET, S. DE NIET, S. LEBRUN, A. PERETZ, F. VANDERBIST
Pain in Europe IV, 4th Congress of the European Federation of IASP Chapters (EFIC), Prague, Tchequie, 2003.
21. Randomised multicentre double-blind placebo-controlled study comparing the efficacy of slow release tramadol with immediate release tramadol in the treatment of symptomatic osteoarthritis of the knee and of the hip
H. MALONNE, M. COFFINER, B. SONET, S. DE NIET, S. LEBRUN, F. VANDERBIST
World Congress on Osteoarthritis, Osteoarthritis Research Society International (OARSI), Berlin, Allemagne, 2003 (publie dans Osteoarthritis Cartilage, 2003, 11(Suppl. A.), S118).
22. L'etoricoxib, un AINS de nouvelle generation?
H. MALONNE
Symposium satellite MSD, Congres europeen "Le Clinicien face a la Douleur Chronique" sous l'egide du College International Francophone de Pathologie Osteo-articulaire, Bruxelles, Belgique, 2004.
23. Phenolic compounds from *Plumbago zeylanica* and their cytotoxicity
A.T. NGUYEN, J. FONTAINE, H. MALONNE, M. VANHAELEN, P. DUEZ.
12eme Forum de la Societe Belge des Sciences Pharmaceutiques, Blankenberghe, Belgique, 2004.
24. Randomised multicentre double-blind study comparing the efficacy of slow release tramadol versus placebo in the treatment of symptomatic osteoarthritis of the knee or the hip
H. MALONNE, M. COFFINER, B. SONET, S. DE NIET, S. LEBRUN, A. SERENO, F. VANDERBIST
Annual European Congress of Rheumatology, European League Against Rheumatism (EULAR), Berlin, Allemagne, 2004 (publie dans Ann. Rheum. Dis., 2004, 63(Suppl.1), 370).
25. Phenylpropanoid and iridoid glycosides from *Scrophularia ningpoensis*
A.T. NGUYEN, J. FONTAINE, M. CLAEYS, F. NSUADI, H. MALONNE, P. DUEZ.
International Congress on Natural Products Research, Phoenix, Arizona, USA, 2004.
26. Experience with ibuprofen lysine in patient with acute mild to moderate pain: Results of the "Paincare" survey
H. MALONNE, D. FONTAINE
3rd WIP Congress, International Institute of Pain, Barcelona, Spain, 2004 (publie dans Pain Pract., 2004, Book of Abstract, 281-2).
27. Synthese des etudes cliniques sur la substitution hormonale
H. MALONNE
Symposium sur la prise en charge de la menopause, Centre Universitaire de Medecine Generale de l'Universite Libre de Bruxelles, Diegem, Belgique, 2004.
28. Cost evaluation of erythropoiesis stimulating agents in the treatment of platinum chemotherapy-induced anaemia
H. MALONNE
20th General Meeting of the Belgian Hematological Society (BHS), Genval, Belgique 2005
29. The Switch from epoetins to darbepoetin in dialysis patients: A cost evaluation

H. MALONNE

Reunion annuelle de la Societe Belge de Nephrologie, Bruxelles, Belgique, 2005.

30. New and cytotoxic compounds from *Disporopsis aspera*

A.T. NGUYEN, J. FONTAINE, , H. MALONNE, P. DUEZ.

53rd Annual Meeting of the Society for Medicinal Plant Research, Florence, Italie, 2005.

31. Structure elucidation and biological evaluation of cytotoxic constituents from *Scrophularia ningpoensis* and *Disporopsis aspera*

A.T. NGUYEN, J. FONTAINE, , H. MALONNE, P. DUEZ.

Journees de l'ecole doctorale en Sciences Pharmaceutiques, Bruxelles, Belgique, 2005.

32. Cost evaluation of the switch from epoetins to darbepoetin in dialysis patients

H. MALONNE

ERA EDTA XLII Congress, Istanbul, Turkey, 2005.

33. Utilization and costs of epoetins and darbepoetin for treating chemotherapy-induced anaemia

H. MALONNE

ECCO-ESTRO, 13th European Conference on Clinical Oncology & 24th Annual Meeting of the European Society for Therapeutic Radiology and Oncology, Paris, France, 2005.

34. Utilization and costs of epoetins and darbepoetin for treating platinum chemotherapy-induced anaemia

H. MALONNE

American Society of Clinical Oncology, Annual Meeting, San Francisco, 2005.

35. PITC is an effective strategy for providing testing services to large numbers of people in a short time in resource-limited settings in South-West China

H. MALONNE

AIDS 2010 XVIII International AIDS Conference, Vienna, Austria, 2010.

36. Study on effect of provider initiated HIV testing and consulting (PITC) at areas inhabited by ethnic minorities with high HIV epidemic

L. CHONGXING, G. YUHAN, L. PENG, L. HUI, L. ZHONGFU, H. YUCHUAN, H. MALONNE

6th IAS Conference on HIV Pathogenesis Treatment and Prevention, Rome, Italy, 2011.

37. Best Practices on HIV/AIDS Comprehensive Prevention and Control in Liang Shan Prefecture, Sichuan Province, People's Republic of China

L. CHONGXING, G. YUHAN, L. PENG, L. HUI, L. ZHONGFU, H. YUCHUAN, H. MALONNE

The 10th International Congress on AIDS in Asia and the Pacific (ICAAP10), Pusan, South Korea, 2011.

Other Relevant Information